Patient outcomes
| Outcome . | No. of patients = 111 . |
|---|---|
| Posttransplant admission within 100 days, n (%) | 30 (27.0) |
| Posttransplant admission diagnosis, n (%) | |
| Febrile, nonneutropenic | 11 (36.7) |
| Febrile neutropenia | 8 (26.7) |
| Cyclosporine toxicity | 5 (16.7) |
| Other* | 6 (20.0) |
| Posttransplant admission duration, median days (range) | 3.5 (1-21) |
| Cause of death, n (%) | 44 (39.6) |
| Disease progression | |
| Relapse | 25 (56.8) |
| cGVHD | 2 (4.5) |
| aGVHD | 1 (2.3) |
| Cyclosporine microangiopathy | 1 (2.3) |
| Infection (bacterial line infection) | 1 (2.3) |
| Cardiac disease | 1 (2.3) |
| Cerebrovascular accident | 1 (2.3) |
| Patient characteristics at last follow-up, n (%) | |
| Alive | 67 (60.4) |
| Duration of follow-up | |
| 1-3 y | 40 (59.7) |
| > 3 y | 27 (40.3) |
| Karnofsky performance status | |
| 100% | 46 (68.7) |
| 90% | 16 (23.9) |
| 80% | 4 (6.0) |
| 70% | 1 (1.5) |
| Immunosuppression, number of medications | |
| No immunosuppression | 46 (68.7) |
| 1 medication | 13 (19.4) |
| 2 medications | 5 (7.5) |
| 3 medications | 3 (4.5) |
| Alive, relapse or disease progression | 20 (29.9) |
| Disease-free interval, median days (range) | 670 (17-2239) |
| Current disease status | |
| CR | 13 (65.0) |
| PR | 6 (30.0) |
| PD | 2 (10.0) |
| Outcome . | No. of patients = 111 . |
|---|---|
| Posttransplant admission within 100 days, n (%) | 30 (27.0) |
| Posttransplant admission diagnosis, n (%) | |
| Febrile, nonneutropenic | 11 (36.7) |
| Febrile neutropenia | 8 (26.7) |
| Cyclosporine toxicity | 5 (16.7) |
| Other* | 6 (20.0) |
| Posttransplant admission duration, median days (range) | 3.5 (1-21) |
| Cause of death, n (%) | 44 (39.6) |
| Disease progression | |
| Relapse | 25 (56.8) |
| cGVHD | 2 (4.5) |
| aGVHD | 1 (2.3) |
| Cyclosporine microangiopathy | 1 (2.3) |
| Infection (bacterial line infection) | 1 (2.3) |
| Cardiac disease | 1 (2.3) |
| Cerebrovascular accident | 1 (2.3) |
| Patient characteristics at last follow-up, n (%) | |
| Alive | 67 (60.4) |
| Duration of follow-up | |
| 1-3 y | 40 (59.7) |
| > 3 y | 27 (40.3) |
| Karnofsky performance status | |
| 100% | 46 (68.7) |
| 90% | 16 (23.9) |
| 80% | 4 (6.0) |
| 70% | 1 (1.5) |
| Immunosuppression, number of medications | |
| No immunosuppression | 46 (68.7) |
| 1 medication | 13 (19.4) |
| 2 medications | 5 (7.5) |
| 3 medications | 3 (4.5) |
| Alive, relapse or disease progression | 20 (29.9) |
| Disease-free interval, median days (range) | 670 (17-2239) |
| Current disease status | |
| CR | 13 (65.0) |
| PR | 6 (30.0) |
| PD | 2 (10.0) |
CR indicates complete remission; PR, partial remission; and PD, progressive disease.
CMV enteritis, n = 1; arrhythmia, n = 1; chest pain, n = 1; acute GVHD, n = 1; GI bleed, n = 1; RSV infection, n = 1.